|
1
|
Whiting DR, Guariguata L, Weil C and Shaw
J: IDF diabetes atlas: Global estimates of the prevalence of
diabetes for 2011 and 2030. Diabetes Res Clin Pract. 94:311–321.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fowler MJ: Microvascular and macrovascular
complications of diabetes. Clinical Diabetes. 26:77–82. 2008.
View Article : Google Scholar
|
|
3
|
Ferrannini E, Gastaldelli A and Iozzo P:
Pathophysiology of prediabetes. Med Clin North Am. 95:327–339,
vii-viii. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
|
|
6
|
Rossing M, Borup R, Henao R, Winther O,
Vikesaa J, Niazi O, Godballe C, Krogdahl A, Glud M, Hjort-Sørensen
C, et al: Down-regulation of microRNAs controlling tumourigenic
factors in follicular thyroid carcinoma. J Mol Endocrinol.
48:11–23. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sand M, Skrygan M, Sand D, Georgas D, Hahn
SA, Gambichler T, Altmeyer P and Bechara FG: Expression of
microRNAs in basal cell carcinoma. Br J Dermatol. 167:847–855.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karolina DS, Armugam A, Tavintharan S,
Wong MT, Lim SC, Sum CF and Jeyaseelan K: MicroRNA 144 impairs
insulin signaling by inhibiting the expression of insulin receptor
substrate 1 in type 2 diabetes mellitus. PLoS One. 6:e228392011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kantharidis P, Wang B, Carew RM and Lan
HY: Diabetes complications: The microRNA perspective. Diabetes.
60:1832–1837. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guay C and Regazzi R: Circulating
microRNAs as novel biomarkers for diabetes mellitus. Nat Rev
Endocrinol. 9:513–521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Creemers EE, Tijsen AJ and Pinto YM:
Circulating microRNAs: Novel biomarkers and extracellular
communicators in cardiovascular disease? Circ Res. 110:483–495.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chien HY, Lee TP, Chen CY, Chiu YH, Lin
YC, Lee LS and Li WC: Circulating microRNA as a diagnostic marker
in populations with type 2 diabetes mellitus and diabetic
complications. J Chin Med Assoc. 78:204–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zampetaki A, Kiechl S, Drozdov I, Willeit
P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E,
et al: Plasma microRNA profiling reveals loss of endothelial
miR-126 and other microRNAs in type 2 diabetes. Circ Res.
107:810–887. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Karolina DS, Tavintharan S, Armugam A,
Sepramaniam S, Pek SL, Wong MT, Lim SC, Sum CF and Jeyaseelan K:
Circulating miRNA profiles in patients with metabolic syndrome. J
Clin Endocrinol Metab. 97:E2271–E2276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang T, Lv C, Li L, Chen S, Liu S, Wang C
and Su B: Plasma miR-126 is a potential biomarker for early
prediction of type 2 diabetes mellitus in susceptible individuals.
Biomed Res Int. 2013:7616172013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rong Y, Bao W, Shan Z, Liu J, Yu X, Xia S,
Gao H, Wang X, Yao P, Hu FB and Liu L: Increased microRNA-146a
levels in plasma of patients with newly diagnosed type 2 diabetes
mellitus. PLoS One. 8:e732722013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao
Y, Dong Q, Pang Z, Guan Q, Gao L, et al: Significance of serum
microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: A
clinical study. Acta Diabetol. 48:61–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Z, Chen H, Si H, Li X, Ding X, Sheng
Q, Chen P and Zhang H: Serum miR-23a, a potential biomarker for
diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol.
51:823–831. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen H, Lan HY, Roukos DH and Cho WC:
Application of microRNAs in diabetes mellitus. J Endocrinol.
222:R1–R10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dehwah MA, Xu A and Huang Q: MicroRNAs and
type 2diabetes/obesity. J Genet Genomics. 39:11–18. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jeon TI, Esquejo RM, Roqueta-Rivera M,
Phelan PE, Moon YA, Govindarajan SS, Esau CC and Osborne TF: An
SREBP-responsive microRNA operon contributes to a regulatory loop
for intracellular lipid homeostasis. Cell Metab. 18:51–61. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang X, Sundquist J, Zöller B, Memon AA,
Palmér K, Sundquist K and Bennet L: Determination of 14 Circulating
microRNAs in Swedes and Iraqis with and without Diabetes Mellitus
Type 2. PLoS One. 9:e867922014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
American Diabetes Association, . Economic
costs of diabetes in the U.S. in 2012. Diabetes Care. 36:1033–1046.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C (T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saeed AI, Sharov V, White J, Li J, Liang
W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, et
al: TM4: A free, open-source system for microarray data management
and analysis. Biotechniques. 34:374–378. 2003.PubMed/NCBI
|
|
27
|
Lu TP, Lee CY, Tsai MH, Chiu YC, Hsiao CK,
Lai LC and Chuang EY: miRSystem: An integrated system for
characterizing enriched functions and pathways of microRNA targets.
PLoS One. 7:e423902012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Oliveros JC; VENNY. An interactive tool
for comparing lists with Venn Diagrams. 2007 http://bioinfogp.cnb.csic.es/tools/venny/index.htmlNovember
20–2013.
|
|
29
|
Dai HJ, Wu JC, Tsai RT, Pan WH and Hsu WL:
T-HOD: A literature-based candidate gene database for hypertension,
obesity and diabetes. Database (Oxford). 2013:bas0612013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang DW, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang DW, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gilad S, Meiri E, Yogev Y, Benjamin S,
Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed
N, et al: Serum microRNAs are promising novel biomarkers. PLoS One.
3:e31482008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang S, Zhao J, Chen Y and Lei M:
Biomarkers associated with ischemic stroke in diabetes mellitus
patients. Cardiovasc Toxicol. 16:213–222. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu H and Leung SW: Identification of
microRNA biomarkers in type 2 diabetes: A meta-analysis of
controlled profiling studies. Diabetologia. 58:900–911. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Collares CV, Evangelista AF, Xavier DJ,
Rassi DM, Arns T, Foss-Freitas MC, Foss MC, Puthier D,
Sakamoto-Hojo ET, Passos GA and Donadi EA: Identifying common and
specific microRNAs expressed in peripheral blood mononuclear cell
of type 1, type 2, and gestational diabetes mellitus patients. BMC
Res Notes. 6:4912013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jeong HJ, Park SY, Yang WM and Lee W: The
induction of miR-96 by mitochondrial dysfunction causes impaired
glycogen synthesis through translational repression of IRS-1 in
SK-Hep1 cells. Biochem Biophys Res Commun. 434:503–508. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Y, Luo H, Li Y, Chen T, Wu S and Yang
L: hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a
promising diagnostic marker in human bladder urothelial carcinomas.
Mol Med Rep. 5:260–265. 2012.PubMed/NCBI
|
|
38
|
Yu JJ, Wu YX, Zhao FJ and Xia SJ: miR-96
promotes cell proliferation and clonogenicity by down-regulating of
FOXO1 in prostate cancer cells. Med Oncol. 31:9102014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fendler A, Jung M, Stephan C, Erbersdobler
A, Jung K and Yousef GM: The antiapoptotic function of miR-96 in
prostate cancer by inhibition of FOXO1. PLoS One. 8:e808072013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu YW, Hu YR, Zhao JY, Li SF, Ma X, Wu SG,
Lu JB, Qiu YR, Sha YH, Wang YC, et al: An agomir of miR-144-3p
accelerates plaque formation through impairing reverse cholesterol
transport and promoting pro-inflammatory cytokine production. PLoS
One. 9:e949972014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ramírez CM, Rotllan N, Vlassov AV, Dávalos
A, Li M, Goedeke L, Aranda JF, Cirera-Salinas D, Araldi E, Salerno
A, et al: Control of cholesterol metabolism and plasma high-density
lipoprotein levels by microRNA-144. Circ Res. 112:1592–1601. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fu X, Huang X, Li P, Chen W and Xia M:
7-Ketocholesterol inhibits isocitrate dehydrogenase 2 expression
and impairs endothelial function via microRNA-144. Free Radic Biol
Med. 71:1–15. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang L, Jia XJ, Jiang HJ, Du Y, Yang F, Si
SY and Hong B: MicroRNAs 185, 96, and 223 repress selective
high-density lipoprotein cholesterol uptake through
posttranscriptional inhibition. Mol Cell Biol. 33:1956–1964. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Meyer JM, Graf GA and van der Westhuyzen
DR: New developments in selective cholesteryl ester uptake. Curr
Opin Lipidol. 24:386–392. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Milagro FI, Miranda J, Portillo MP,
Fernandez-Quintela A, Campión J and Martínez JA: High-throughput
sequencing of microRNAs in peripheral blood mononuclear cells:
Identification of potential weight loss biomarkers. PLoS One.
8:e543192013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Best LG, García-Esquinas E, Yeh JL, Yeh F,
Zhang Y, Lee ET, Howard BV, Farley JH, Welty TK, Rhoades DA, et al:
Association of diabetes and cancer mortality in American Indians:
The strong heart study. Cancer Causes Control. 26:1551–1560. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Onitilo AA, Stankowski RV, Berg RL, Engel
JM, Glurich I, Williams GM and Doi SA: Type 2 diabetes mellitus,
glycemic control, and cancer risk. Eur J Cancer Prev. 23:134–140.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Qi L, Qi X, Xiong H, Liu Q, Li J, Zhang Y,
Ma X, Wu N, Liu Q and Feng L: Type 2 diabetes mellitus and risk of
malignant melanoma: A systematic review and meta-analysis of cohort
studies. Iran J Public Health. 43:857–866. 2014.PubMed/NCBI
|
|
49
|
Vavallo A, Simone S, Lucarelli G,
Rutigliano M, Galleggiante V, Grandaliano G, Gesualdo L, Campagna
M, Cariello M, Ranieri E, et al: Pre-existing type 2 diabetes
mellitus is an independent risk factor for mortality and
progression in patients with renal cell carcinoma. Medicine
(Baltimore). 93:e1832014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Brodovicz KG, Kou TD, Alexander CM,
O'Neill EA, Engel SS, Girman CJ and Goldstein BJ: Impact of
diabetes duration and chronic pancreatitis on the association
between type 2 diabetes and pancreatic cancer risk. Diabetes Obes
Metab. 14:1123–1128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lan F, Yu H, Hu M, Xia T and Yue X:
miR-144-3p exerts anti-tumor effects in glioblastoma by targeting
c-Met. J Neurochem. 135:274–286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chang CW, Wu HC, Terry MB and Santella RM:
microRNA expression in prospectively collected blood as a potential
biomarker of breast cancer risk in the BCFR. Anticancer Res.
35:3969–3977. 2015.PubMed/NCBI
|
|
53
|
Stokowy T, Eszlinger M, Świerniak M,
Fujarewicz K, Jarząb B, Paschke R and Krohn K: Analysis options for
high-throughput sequencing in miRNA expression profiling. BMC Res
Notes. 7:1442014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lu ZM, Lin YF, Jiang L, Chen LS, Luo XN,
Song XH, Chen SH and Zhang SY: Micro-ribonucleic acid expression
profiling and bioinformatic target gene analyses in laryngeal
carcinoma. Onco Targets Ther. 7:525–533. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Swierniak M, Wojcicka A, Czetwertynska M,
Stachlewska E, Maciag M, Wiechno W, Gornicka B, Bogdanska M,
Koperski L, de la Chapelle A and Jazdzewski K: In-depth
characterization of the microRNA transcriptome in normal thyroid
and papillary thyroid carcinoma. J Clin Endocrinol Metab.
98:E1401–E1409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Matamala N, Vargas MT, González-Cámpora R,
Miñambres R, Arias JI, Menéndez P, Andrés-León E, Gómez-López G,
Yanowsky K, Calvete-Candenas J, et al: Tumor MicroRNA expression
profiling identifies circulating MicroRNAs for early breast cancer
detection. Clin Chem. 61:1098–1096. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kara M, Yumrutas O, Ozcan O, Celik OI,
Bozgeyik E, Bozgeyik I and Tasdemir S: Differential expressions of
cancer-associated genes and their regulatory miRNAs in colorectal
carcinoma. Gene. 567:81–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang L, Zhu MJ, Ren AM, Wu HF, Han WM, Tan
RY and Tu RQ: A ten-microRNA signature identified from a
genome-wide microRNA expression profiling in human epithelial
ovarian cancer. PLoS One. 9:e964722014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li C, Du X, Tai S, Zhong X, Wang Z, Hu Z,
Zhang L, Kang P, Ji D, Jiang X, et al: GPC1 regulated by miR-96-5p,
rather than miR-182-5p, in inhibition of pancreatic carcinoma cell
proliferation. Int J Mol Sci. 15:6314–6327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Larne O, Martens-Uzunova E, Hagman Z,
Edsjö A, Lippolis G, den Berg MS, Bjartell A, Jenster G and Ceder
Y: miQ-a novel microRNA based diagnostic and prognostic tool for
prostate cancer. Int J Cancer. 132:2867–2875. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wu X, Ding N, Hu W, He J, Xu S, Pei H, Hua
J, Zhou G and Wang J: Down-regulation of BTG1 by miR-454-3p
enhances cellular radiosensitivity in renal carcinoma cells. Radiat
Oncol. 9:1792014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shoshan E, Mobley AK, Braeuer RR, Kamiya
T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, et al:
Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma
growth and metastasis. Nat Cell Biol. 17:311–321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Liu C, Iqbal J, Teruya-Feldstein J, Shen
Y, Dabrowska MJ, Dybkaer K, Lim MS, Piva R, Barreca A, Pellegrino
E, et al: MicroRNA expression profiling identifies molecular
signatures associated with anaplastic large cell lymphoma. Blood.
122:2083–2092. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Sand M, Skrygan M, Sand D, Georgas D, Hahn
SA, Gambichler T, Altmeyer P and Bechara FG: Expression of
microRNAs in basal cell carcinoma. Br J Dermatol. 167:847–855.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hiroki E, Akahira J, Suzuki F, Nagase S,
Ito K, Suzuki T, Sasano H and Yaegashi N: Changes in microRNA
expression levels correlate with clinicopathological features and
prognoses in endometrial serous adenocarcinomas. Cancer Sci.
101:241–249. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Saito K, Inagaki K, Kamimoto T, Ito Y,
Sugita T, Nakajo S, Hirasawa A, Iwamaru A, Ishikura T, Hanaoka H,
et al: MicroRNA-196a is a putative diagnostic biomarker and
therapeutic target for laryngeal cancer. PLoS One. 8:e714802013.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Bai R, Weng C, Dong H, Li S, Chen G and Xu
Z: MicroRNA-409-3p suppresses colorectal cancer invasion and
metastasis partly by targeting GAB1 expression. Int J Cancer.
137:2310–2322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Xu X, Chen H, Lin Y, Hu Z, Mao Y, Wu J, Xu
X, Zhu Y, Li S, Zheng X and Xie L: MicroRNA-409-3p inhibits
migration and invasion of bladder cancer cells via targeting c-Met.
Mol Cells. 36:62–88. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Josson S, Gururajan M, Hu P, Shao C, Chu
GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, et al: miR-409-3p/−5p
promotes tumorigenesis, epithelial-to-mesenchymal transition, and
bone metastasis of human prostate cancer. Clin Cancer Res.
20:4636–4646. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Li C, Nie H, Wang M, Su L, Li J, Yu B, Wei
M, Ju J, Yu Y, Yan M, et al: MicroRNA-409-3p regulates cell
proliferation and apoptosis by targeting PHF10 in gastric cancer.
Cancer Lett. 320:189–197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Cuk K, Zucknick M, Heil J, Madhavan D,
Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, et al:
Circulating microRNAs in plasma as early detection markers for
breast cancer. Int J Cancer. 132:1602–1612. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X,
Yu L, Wang L, Wang J, Wu Y, et al: A plasma microRNA panel for
early detection of colorectal cancer. Int J Cancer. 136:152–161.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Chen J, Sun D, Chu H, Gong Z, Zhang C,
Gong B, Li Y, Li N and Jiang L: Screening of differential microRNA
expression in gastric signet ring cell carcinoma and gastric
adenocarcinoma and target gene prediction. Oncol Rep. 33:2963–2971.
2015.PubMed/NCBI
|
|
74
|
Wang Q, Zhao Z, Shang J and Xia W: Targets
and candidate agents for type 2 diabetes treatment with
computational bioinformatics approach. J Diabetes Res.
2014:7639362014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Jain P, Vig S, Datta M, Jindel D, Mathur
AK, Mathur SK and Sharma A: Systems biology approach reveals genome
to phenome correlation in type 2 diabetes. PLoS One. 8:e535222013.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Dinh W, Lankisch M, Nickl W, Scheyer D,
Scheffold T, Kramer F, Krahn T, Klein RM, Barroso MC and Füth R:
Insulin resistance and glycemic abnormalities are associated with
deterioration of left ventricular diastolic function: A
cross-sectional study. Cardiovasc Diabetol. 9:632010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Shigematsu Y, Hamada M, Nagai T, Nishimura
K, Inoue K, Suzuki J, Ogimoto A and Higaki J: Risk for atrial
fibrillation in patients with hypertrophic cardiomyopathy:
Association with insulin resistance. J Cardiol. 58:18–25. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Okayama S, Soeda T, Kawakami R, Takami Y,
Somekawa S, Ueda T, Sugawara Y, Matsumoto T, Sung JH, Nishida T, et
al: Evaluation of coronary artery disease and cardiac morphology
and function in patients with hypertrophic cardiomyopathy, using
cardiac computed tomography. Heart Vessels. 30:28–35. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Diniz GP, Carneiro-Ramos MS and
Barreto-Chaves ML: Angiotensin type 1 receptor mediates thyroid
hormone-induced cardiomyocyte hypertrophy through the
Akt/GSK-3beta/mTOR signaling pathway. Basic Res Cardiol.
104:653–667. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Marin TM, Keith K, Davies B, Conner DA,
Guha P, Kalaitzidis D, Wu X, Lauriol J, Wang B, Bauer M, et al:
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of
LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest.
121:1026–1043. 2011. View Article : Google Scholar : PubMed/NCBI
|
